Autopsy report · NCT05504642

Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients

“Study stopped before submission for funding reasons”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Universitätsklinikum Köln

Sponsor type

University, hospital or other

Conditions

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases

Interventions

Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab); Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab); Maintenance Treatment (Nivolumab/Ipilimumab)

Participants

0

Trials that died the same way

• Assessment of Pulmonary Congestion During Cardiac Hemodynamic Stress Testing
  “Study was stopped due to funding and time constraints.” (84% match in meaning)
• Tiotropium Handihaler vs. Tiotropium Respimat in COPD
  “Study halted prematurely due to funding, prior to enrollment of first participant” (83% match in meaning)
• PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor
  “Study delays and ran out of funding” (81% match in meaning)
• Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
  “Funding for study was withdrawn” (79% match in meaning)
• Pasireotide in Hyperinsulinemic Hypoglycemia
  “Funding was withdrawn by Sponsor prior to start of study” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.